Evofem Biosciences Stock Retained Earnings
EVFMDelisted Stock | USD 0.05 0.0001 0.21% |
Evofem Biosciences fundamentals help investors to digest information that contributes to Evofem Biosciences' financial success or failures. It also enables traders to predict the movement of Evofem OTC Stock. The fundamental analysis module provides a way to measure Evofem Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Evofem Biosciences otc stock.
Evofem |
Evofem Biosciences OTC Stock Retained Earnings Analysis
Evofem Biosciences' Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current Evofem Biosciences Retained Earnings | (526.68 M) |
Most of Evofem Biosciences' fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Evofem Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
CompetitionBased on the latest financial disclosure, Evofem Biosciences has a Retained Earnings of (526.68 Million). This is 156.55% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The retained earnings for all United States stocks is 105.65% higher than that of the company.
Evofem Retained Earnings Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Evofem Biosciences' direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Evofem Biosciences could also be used in its relative valuation, which is a method of valuing Evofem Biosciences by comparing valuation metrics of similar companies.Evofem Biosciences is currently under evaluation in retained earnings category among its peers.
Evofem Fundamentals
Return On Equity | -3.87 | ||||
Return On Asset | -1.25 | ||||
Operating Margin | (5.41) % | ||||
Current Valuation | 112.69 M | ||||
Shares Outstanding | 121.22 M | ||||
Shares Owned By Insiders | 0.28 % | ||||
Shares Owned By Institutions | 0.57 % | ||||
Number Of Shares Shorted | 8.68 M | ||||
Price To Earning | (1.26) X | ||||
Price To Book | 8.37 X | ||||
Price To Sales | 0.42 X | ||||
Revenue | 8.24 M | ||||
Gross Profit | 4.19 M | ||||
EBITDA | (204.14 M) | ||||
Net Income | (205.19 M) | ||||
Cash And Equivalents | 19.89 M | ||||
Cash Per Share | 0.23 X | ||||
Total Debt | 125.74 M | ||||
Debt To Equity | 8.72 % | ||||
Current Ratio | 0.16 X | ||||
Book Value Per Share | (0.77) X | ||||
Cash Flow From Operations | (146.67 M) | ||||
Short Ratio | 0.19 X | ||||
Earnings Per Share | (19.01) X | ||||
Target Price | 2.9 | ||||
Number Of Employees | 119 | ||||
Beta | -1.25 | ||||
Market Capitalization | 6.41 M | ||||
Total Asset | 42.51 M | ||||
Retained Earnings | (526.68 M) | ||||
Working Capital | 3.78 M | ||||
Current Asset | 16.39 M | ||||
Current Liabilities | 12.61 M | ||||
Z Score | -30.0 | ||||
Net Asset | 42.51 M |
About Evofem Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Evofem Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Evofem Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Evofem Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in census. Note that the Evofem Biosciences information on this page should be used as a complementary analysis to other Evofem Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Consideration for investing in Evofem OTC Stock
If you are still planning to invest in Evofem Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Evofem Biosciences' history and understand the potential risks before investing.
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation |